Skip to main content

Table 4 Characteristics that are statistically different between patients with high serum TNC and high serum IgE levels and others

From: Characterization of tenascin-C as a novel biomarker for asthma: utility of tenascin-C in combination with periostin or immunoglobulin E

  High TNC > 37.16 Low TNC < 37.16 High TNC > 37.16 Low TNC < 37.16 P value for multigroup analysis Groups B, C and D P value between groups A and E
High IgE > 100 High IgE > 100 Low IgE < 100 Low IgE < 100
A (n = 36) B (n = 42) C (n = 16) D (n = 32) E (n = 90)
GINA step 4 + 5, n (%) 29 (80.6) 18 (42.9) 13 (81.3) 21 (65.6) 0.002* 52 (57.8) 0.023*
Peripheral neutrophils (cells/μL) 4593.71 ± 1656.42 3823.77 ± 1249.02 3832.20 ± 1117.89 3735.33 ± 1637.25 0.018* 3793.82 ± 1365.61 0.002*
Peripheral eosinophils (cells/μL) 338.37 ± 302.52 287.01 ± 206.42 214.70 ± 194.18 172.96 ± 172.63 0.027* 233.60 ± 197.73 0.170
Serum IgE (IU/mL) 1120.92 ± 2424.39 831.76 ± 1733.44 46.26 ± 28.61 51.09 ± 25.59 < 0.001* 414.55 ± 1240.42 < 0.001*
Th2-high, n (%) 23 (63.9) 30 (71.4) 0 (0.0) 0 (0.0) < 0.001* 30 (33.3) 0.003*
Serum TNC (ng/mL) 63.77 ± 29.77 26.04 ± 8.42 53.79 ± 12.95 22.65 ± 7.29 < 0.001* 29.77 ± 14.42 < 0.001*
%FVC (predicted, %) 97.08 ± 12.80 105.44 ± 16.51 107.59 ± 16.01 104.40 ± 18.16 NS 105.45 ± 16.88 0.005*
%FEV1 (predicted, %) 82.77 ± 15.57 94.92 ± 16.70 95.69 ± 19.99 92.69 ± 20.27 0.005* 94.26 ± 18.45 < 0.001*
%PEF (predicted, %) 96.95 ± 19.02 103.93 ± 19.00 107.31 ± 24.44 107.53 ± 23.42 0.124 105.81 ± 21.48 0.033*
%MMF (predicted, %) 48.56 ± 20.87 63.05 ± 24.47 63.56 ± 32.29 62.88 ± 32.92 0.083 63.08 ± 28.79 0.010*
  1. Data are presented as the mean ± standard deviation unless otherwise indicated
  2. ACT asthma control test, AERD aspirin-exacerbated respiratory disease, BMI body mass index, FeNO fractional exhaled nitric oxide, FEV1 forced expiratory volume in 1 s, FP fluticasone propionate, FVC forced vital capacity, GINA Global Initiative for Asthma, ICS inhaled corticosteroid, IgE immunoglobulin E, MMF mid-maximal flow rate, OCS oral corticosteroids, PEF peak expiratory flow, PSL prednisolone, Th2 T-helper cell type 2, TNC tenascin-C, NS not significant
  3. *P < 0.05
  4. †Multigroup analysis performed by Chi square test, One-way ANOVA and Kruskal–Wallis test as appropriate
  5. ‡Comparisons performed by Student’s t test, the Mann–Whitney U test, and Fisher’s exact test as appropriate
\